

LEGAL NOTICE

EPIDEMIOLOGICAL STUDIES ON RADIATION CARCINOGENESIS
IN HUMAN POPULATIONS FOLLOWING ACUTE EXPOSURE:
NUCLEAR EXPLOSIONS AND MEDICAL RADIATION^{1,2}

Jacob I. Fabrikant, MD, Ph.D.^{3,4}

Lawrence Berkeley Laboratory

Donner Laboratory

University of California, Berkeley

and

Department of Radiology
University of California School of Medicine
San Francisco

for review

MASTER

DISCLAIMER

1 Presented at the Symposium on Effects on Humans of Exposure to Low Levels of Ionizing Radiation, Yale University School of Medicine, New Haven, CT, May 14, 1981, and published in the Yale Journal of Biology and Medicine, Vol. 54 (1981), pp. 457-469.

2 Supported by the Office of Health and Environmental Research of the U.S. Department of Energy under Contract DE-AC03-76SF00098, and the Environmental Protection Agency.

3 Professor of Radiology, University of California School of Medicine, San Francisco.

4 Address reprint requests to: Jacob I. Fabrikant, M.D., Ph.D., Donner Laboratory, University of California, Berkeley, California 94720.

ABSTRACT

The present review provides an understanding of our current knowledge of the carcinogenic effect of low-dose radiation in man, and surveys the epidemiological studies of human populations exposed to nuclear explosions and medical radiation. Discussion centers on the contributions of quantitative epidemiology to present knowledge, the reliability of the dose-incidence data, and those relevant epidemiological studies that provide the most useful information for risk estimation of cancer-induction in man. Reference is made to dose-incidence relationships from laboratory animal experiments where they may obtain for problems and difficulties in extrapolation from data obtained at high doses to low doses, and from animal data to the human situation. The paper describes the methods of application of such epidemiological data for estimation of excess risk of radiation-induced cancer in exposed human populations, and discusses the strengths and limitations of epidemiology in guiding radiation protection philosophy and public health policy.

INTRODUCTION

Cancer-induction is the most important late somatic health effect of low-dose ionizing radiation (1), and as the dose of radiation increases above low levels, the risk of cancer increases in exposed human populations. It is these observations that have been central to public concern about the potential health effects of low-level radiation, and to the task of estimating risks and establishing standards for protection of the health of the public. Epidemiological surveys on exposed human populations presently provide the scientific basis for risk estimation, but the data are highly uncertain in regard to the forms of the dose-response relationships for radiation-induced cancer, and this is especially the case for low-level radiation. Therefore, it has been necessary to estimate human cancer risk at low radiation doses primarily from observations at relatively high doses in human populations exposed to nuclear explosions and medical radiation. Since it is not known whether the cancer incidence observed at such high dose levels also applies to cancer-induction at low dose levels, scientific disagreement can arise concerning the methods to be used for estimating the carcinogenic risk from low-level radiation.

The present paper reviews the relevant epidemiological surveys on radiation carcinogenesis in human populations exposed to nuclear explosions or medical radiation, describes the methods of application of such epidemiological data for estimation of excess cancer risk in these exposed populations, and discusses the strengths and limitations of epidemiology in guiding radiation protection philosophy and public policy.

What Do We Know About Radiation Carcinogenesis?

The somatic effects of concern at low doses and low dose rates are those that may be induced by mutation in individual cells, singly or in small numbers. The most important of these is considered to be cancer induction. Current knowledge of the carcinogenic effect of radiation in man has been reviewed to two recent reports: the 1977 Report of the United Nations Scientific Committee on the Effects of Atomic Radiation, the 1977 UNSCEAR Report, and the 1980 Report of the National Academy of Sciences Committee on the Biological Effects of Ionizing Radiations, the BEIR-III Report (1,2). The epidemiological data analyzed in these reports derive mainly from the epidemiological studies of the Japanese atomic bomb survivors in Hiroshima and Nagasaki, from patients in England and Wales treated with X irradiation for ankylosing spondylitis, and from several other groups of people irradiated from external or internal sources, either for medical reasons or from occupational exposure. Both reports emphasize that cancers of the breast, thyroid, hemopoietic tissues, lung, and bone can be induced by radiation. Other cancers, including cancers of the stomach, pancreas, pharynx, lymphatic cancer, and perhaps all tissues of the body, may also be induced by radiation. Both reports derive risk estimates in absolute and relative terms for low-dose, low-LET* whole body exposure, and for leukemia, breast cancer, thyroid cancer, lung cancer, and other cancers. These estimates derive from exposure and cancer incidence data at high doses (most frequently greater than 50 rem) **

* Linear energy transfer (abbr. LET) is the average amount of energy lost per unit of particle spur-track length. Low-LET: radiation characteristic of electrons, X rays and gamma rays. High LET: radiation characteristic of protons, fast neutrons and alpha particles.

** rem is the unit of radiation dose equivalent = absorbed dose (in rads) times quality factor times distribution factor times any other necessary modifying factors.

and at high dose rates (most frequently greater than 50 rems per minute) (1,3). There are no compelling scientific reasons to apply these values of risk per rem derived from high doses and high dose rates to the very low doses and low dose rates of concern in human radiation protection. In the absence of reliable human data for calculating risk estimates at very low doses and low dose rates, neither the UNSCEAR nor BEIR Committees felt confident to predict the reliability of such extrapolation (1-4).

Certain general principles of radiation carcinogenesis have now emerged based on the relatively large number of epidemiological surveys studied. Firstly, the younger the exposed individual, from in utero exposure through adult life, the higher is the risk per rem for induction of most tumors. Secondly, the incidence of leukemia in exposed populations rises above normal within 3 to 5 years of exposure, and declines within 15 to 20 years, but persists for 25 years or more after exposure. The elevated induction rate for solid tumors becomes apparent after a latent period of 10 to 15 years following exposure in adults, and then persists for an unknown period, in some cancers for over 30 to 35 years. Few irradiated populations have, as yet, been studied for more than 30 years. Thirdly, whereas initially leukemia was considered the most sensitive index of radiation carcinogenesis in man, the excess of solid tumors in irradiated populations now exceeds that of leukemias by a significant factor (1). And lastly, comparison of epidemiological data obtained from human populations exposed to very different dose rates to ascertain whether there is a reduction in risk per rem at low dose rates can not, as yet, be reliably made for different types of neoplasms. In the case of leukemia and for radiation-induced breast cancer, the evidence suggests that there may be little or no dose-rate effect. Fractionation of the total dose given over several years

thus far yields excess leukemia and breast cancer risk estimates that are not significantly different from those obtained from single-dose epidemiological surveys (1,2).

What Can We Learn from Dose-Incidence Data in Animals for Extrapolation to Man?

Benign and malignant tumors of almost any type or site may be induced by irradiation in animals. Susceptability to radiation carcinogenesis varies widely among cells, tissues, organs, and organisms, depending on the influences of species differences, genetic composition, age, sex, physiological state, and other constitutional and environmental factors. Although all ionizing radiations are qualitatively similar in carcinogenic activity, they vary considerably in carcinogenic effectiveness per rad,* depending on the dose and on the distribution of the radiation in time and space (1-9).

The dose-incidence relationship for cancer induction has not been characterized sufficiently over a wide range of radiation doses, dose rates, and LET to enable risk estimation at doses, say, below 25 rems. Wide variations occur in the shapes of the dose-response curves for cancers of different types and for cancers of the same type. The incidence of tumors to be expected under determined exposure conditions cannot be predicted reliably by extrapolation from observations in animals or in man in other neoplasms or other exposure conditions (1-7).

In spite of the uncertainties in dose-incidence relationships the following important generalizations emerge from the extensive laboratory animal data available. The incidence of cancer is increased by irradiation; the dose-response curve rises with dose up to a certain dose level, above which it may reach a plateau and turn downward with further increase in dose. In the dose

* rad is the unit of absorbed dose of radiation = 100 ergs/g.

range over which the incidence increases with dose, low-LET radiations are usually more effective at high doses and high dose rates than at low doses and low dose rates. In the same dose range, high-LET radiations are usually more effective than low-LET radiations. For high-LET radiations, the effectiveness is influenced less by dose and dose rate, and in some instances, protraction may increase their effectiveness. The relative biological effectiveness* (RBE) of high-LET radiations tends to increase with decreasing dose and dose rate (1-10). Because of wide species differences in response in laboratory animals, the cancer dose-incidence response for any species cannot provide a reliable basis for direct quantitative risk estimates for cancer-induction in man. Furthermore, variations in the shapes of dose-incidence curves for different radiation-induced neoplasms in laboratory animals confound extrapolation from one type of neoplasms to another, from any one set of exposure conditions to another, or from any one animal species to another, and particularly to man.

What Can We Learn from High Dose Data for Extrapolation to Low Doses?

Because of the difficulty of obtaining reliable cancer-incidence data in laboratory animals and in humans for low doses, for purposes of risk estimation dose-response relationships observed at high doses must necessarily be extrapolated into the low-dose region, where reliable human epidemiological data are not available. It is impossible to ascertain the true shape of the dose-effect curve at low dose levels, and therefore the mechanism of radiation action in the low-dose region (1). Consideration of the spatial and temporal distribution of ionizations suggests that at very low dose levels, the probability of interaction of ionizing events is negligible. Here, the molecular and cellular

* relative biological effectiveness (abbr. RBE) is defined as the ratio of the absorbed radiation dose of high-LET radiation which produces the same biological effect as that due to a dose of low-LET radiation.

response to radiation at very low doses must be linear with dose, irrespective of the shape of the dose-response curve at higher doses. It is reasonable, as well, that the dose-response relationship for cancer-incidence at very low doses will be linear, irrespective of the complexity of the carcinogenic process.

The recent conclusion of the BEIR Committee (1), and those of the NCRP* (9,11), the ICRP** (12), and the UNSCEAR (2) Committees, is that it is reasonable to assume for low-LET radiation a linear-quadratic dose-response relationship for cancer-induction, with linearity predominating at the very low doses, and to assume linear extrapolation at very low doses for the purpose of human risk estimation. This leads to conservatism, that is, an overestimation of risk. Such extrapolations depend on existing epidemiological data from much higher doses, which are the lowest doses that have been estimated and reliably tested.

Because of these uncertainties and limitations in the epidemiological studies, experimental animal studies must provide essential information; however, human risk estimation cannot be based directly on laboratory animal data. Nevertheless, the evidence suggests that mechanisms of cancer induction in man are similar to those in laboratory animals. It follows, therefore, that while experimental animal data are not quantitatively or directly applicable to man, dose-response relationships in animal studies may be considered for application to human populations exposed to low-level radiation (5,7,9,13).

* National Council on Radiation Protection and Measurements (abbr. NCRP)

** International Commission on Radiological Protection (abbr. ICRP).

In recent years, a general hypothesis for estimation of excess cancer risk in irradiated human populations, based on theoretical considerations, on extensive laboratory animal studies, and on limited epidemiological surveys, suggests various and complex dose-response relationships between radiation dose and observed cancer incidence (7,13-16). One of the most widely considered models for cancer-induction by radiation, based on the available information and consistent with both knowledge and theory, takes the complex quadratic form: $I(D) = (\alpha_0 + \alpha_1 D + \alpha_2 D^2) \exp(-\beta_1 D - \beta_2 D^2)$, where I is the cancer incidence in the irradiated population at radiation dose D in rad, and α_0 , α_1 , α_2 , β_1 and β_2 are non-negative constants (Fig. 1). This multicomponent dose-response curve contains (1) initial upward-curving linear and quadratic functions of dose, which represent the process of cancer-induction by radiation, and (2) a modifying exponential function of dose, which represents the competing effect of cell-killing at high doses. α_0 is the ordinate intercept at 0 dose, and defines the natural incidence of cancer in the population. α_1 is the initial slope of the curve at 0 dose, and defines the linear component in the low-dose range. α_2 is the curvature near 0 dose, and defines the upward-curving quadratic function of dose. β_1 and β_2 are the slopes of the downward-curving function in the high-dose range, and define the cell-killing function. Analysis of a number of dose-incidence curves for cancer-induction in irradiated populations, both in humans and in animals, has demonstrated that for different radiation-induced cancers only certain of the parameter values of these constants can be theoretically determined. Therefore, it has become necessary to simplify the model by reducing the number of parameters and eliminating those which would have the least effect on the form of the dose-response relationship in the dose range of low-level radiation. Such simpler models, with increasing complexity, include the linear, the pure

quadratic, the quadratic (quadratic function with a linear term in the low-dose region), and finally, the multi-component quadratic form with a linear term and with an exponential modifier (1,3,7,9,13-15) (Fig. 2).

What Have We Learned from the Epidemiological Studies of Human Populations?

Nuclear Explosions

The most valuable human data available for evaluation of the late effects of radiation come from the studies of the Atomic Bomb Casualty Commission, now in the Radiation Effects Research Foundation,* on the Japanese A-bomb survivors in Hiroshima and Nagasaki (17). The continuing evalation of this population provides the most comprehensive assessment of risk estimates for the carcinogenic effect of radiation. The study population is the largest of any epidemiological survey (over 100,000 persons), and these persons were irradiated for other than medical reasons. The A-bomb survivors were exposed at all ages and the radiation doses ranged from a few rads to near-lethal levels.

What are the important questions concerning the mortality experience of the atomic bomb survivors? Is radiation carcinogenesis the only important late effect from the standpoint of mortality? Is the carcinogenic effect a general one, affecting all tissues and histologic types? Are there reliable city differences from which relative biological effectiveness estimates can be made? Are Nagasaki data numerous enough to permit any close examination of the functional form of the gamma dose-response curve for specific cancers? Can further insight be gained into the role of age in 1945 at the time of the bomb upon the carcinogenic effect of ionizing radiation?

* Radiation Effects Research Foundation (abbr. RERF). Japanese Foundation chartered by the Japanese Welfare Ministry under an agreement between the United States and Japan.

These studies are attempting to answer the important questions with direct bearing on estimation of the cancer risk in human populations exposed to low-dose levels. The magnitude of risk of induction of all types of solid tumors in relation to dose and time since exposure require careful evaluation. The excess risk of leukemia following irradiation increased with dose; after high doses it was evident within 3 to 4 years after radiation and declined within 15 years, but persisted for 25 years or more after exposure (17-19). At present, there continues to be a large increase in the radiation-induced cancer death rate during the 10-year period 1965 to 1974, up to 30 years after exposure. This increase is in solid tumor induction; there is presently no indication of a return to normal levels of the mortality rates from these cancers. Other types of cancer are occurring in excess in the surviving irradiated population, due mainly to extremely long latent periods after exposure before these solid tumors are detected. Recently, certain cancers not previously thought to be radiation-induced are appearing in excess in the irradiated population. And finally, the method of radiation action--whether to multiply or to add to spontaneous levels of the cancer death rate--is essential information for projecting the long-term carcinogenic effects in persons irradiated as children or young adults.

Present cancer risk estimates predicted to occur as a result of low-dose exposure of human populations to radiation rely on assumptions about these important questions and on assumptions on the method of extrapolation from human data obtained at high doses to low doses. At the present time, estimated excess cancer rates are derived from observations on Japanese A-bomb survivors of Hiroshima and Nagasaki averaged over the period 1960 to 1974. The excess cancer death rate of these survivors could rise, remain the same, or decrease during the coming years. For leukemia induction in the Nagasaki survivors, the

Life span Study* (LSS) death certificate data appear consistent with a quadratic dose-incidence relationship (Fig. 3). The shape of the Nagasaki curve is considered a strong determinant of the value for the RBE for neutrons derived from the Hiroshima (neutron-rich) and Nagasaki (neutron-deficient) exposure (17,19).

The leukemia dose-response curves in the LSS sample and the Leukemia Registry in the two cities are compared in Fig. 3 (17). An apparent curvilinear relationship in the low-dose region results from the sparsity of leukemia cases in the Nagasaki LSS sample below 100 rads kerma; this relationship is much less marked when all the Registry cases are used. The leukemia incidence in the Nagasaki LSS sample is less than in the Hiroshima survivors at all doses except in the 0-9 rads group. This increased incidence in the Hiroshima survivors implies a greater RBE for neutrons for leukemia-induction than gamma rays, and the neutron RBE is greater than one. The curvilinearity in the Nagasaki sample indicates that the neutron RBE increases as the dose diminishes (18,19). This is believed to be due to greater repair capacity of effects of low dose, low-LET gamma radiation, rather than increased damage per unit of high-LET neutron radiation (18).

Another population that received irradiation as a result of a nuclear explosion was the Marshall Islanders, who were exposed to fallout from an H-bomb test explosion in 1954 (20). In this population, the main health effects came from short-lived fission iodine radioisotopes; this has contributed to our knowledge of risk estimates for thyroid cancer following irradiation. However, the data on the Marshallese are difficult to analyze,

* Life Span Study (abbr. LSS) of the Japanese atomic-bomb survivors; sample consists of 109,000 persons, of whom 82,000 were exposed to the bombs, mostly at low doses.

primarily because their radiation exposures were to a mixture of high dose rate external and internal gamma photons, as well as to beta radiation.

Medical Radiation Exposures

The initial reports of Stewart and her colleagues (21) described an excess of leukemia and all other cancers among children irradiated in utero when their mothers received diagnostic pelvic X-irradiation during the pregnancy. The two largest studies (22,23) indicated that diagnostic pelvic X-ray examinations during pregnancy resulted in an increase of approximately 50 percent in cancer mortality among the children during the first 10 years of life. Because the doses involved an average dose of about 1 rad to the fetus, these surveys are extremely important to radiation protection of the general population. However, failure to confirm these results in the children of the Japanese women who were exposed to atom-bomb radiation in Hiroshima and Nagasaki, and the inability to reproduce the result in laboratory animals, has led to the questioning of whether radiation alone is the etiologic agent in the human surveys (38).

Several other human populations exposed to diagnostic X-rays have been studied. Multiple diagnostic exposure to adult males appears to be associated with the increased risk of developing leukemia (23). The risk estimates for leukemia-induction from this study are similar to those obtained from data at high doses of radiation.

Studies that increase the precision of risk estimates for induction of breast cancer are those of a follow-up of pulmonary tuberculosis patients for whom the treatment of choice prior to 1950 was artificial pneumothorax, which was associated with repeated fluoroscopic exposures. The initial surveys of female patients treated in a Nova Scotia sanatorium between 1940 and 1949 (24,25) indicated that despite the uncertainty of the radiation dose estimates

and the extreme fractionation of the total dose, the risk per rad for breast cancer-induction is large and very similar to single-exposure studies, in which high doses were absorbed by the breast tissue (17). These data appear consistent with a linear dose-incidence relationship (16) (Fig. 4).

Important information has been obtained from persons who have been irradiated either externally or by internal emitters for therapeutic reasons. Court-Brown and Doll (26) analyzed the data on leukemia and all other cancers in over 14,000 patients with ankylosing spondylitis who received external irradiation from 1935 to 1954 in the United Kingdom. The leukemia data in these patients are in reasonably good agreement with those from the Japanese A-bomb survivors. Another study of patients irradiated for ankylosing spondylitis and other diseases is that of Spiess and Mays (27,28); here, the patients received intravenous injections of the bone-seeking alpha-emitter radium-224. The evidence indicates that the younger patients are slightly more susceptible to the induction of bone sarcomas for equal protraction periods and that the data are consistent with a quadratic dose-incidence relationship.

Irradiation for medical reasons often introduces uncertainties into the interpretation of data from patients, particularly the potential influence of the disease for which the patients were treated. Furthermore, analysis of the dose-incidence relationships for carcinogenesis by internal emitters is complicated by several sources of uncertainty relating to variations in the spatial and temporal distribution of the dose, which are, in turn, dependent on the uptake, disposition, metabolism, and elimination of the radionuclide (1-8,29). In most patients, the initial dose, dose rate, and patterns of radionuclide excretion are unknown. Furthermore, the radioactivity in these individuals may be deposited nonuniformly in bone, and concentrated in hot spots where the dose at the center is very much higher than that in surrounding bone (29).

Occupational Exposures

Valuable epidemiological surveys exist on populations of workers exposed as a result of their occupations; these include, for example, uranium and fluorspar miners, radiologists, radium-dial painters, and workers in the processing of plutonium (1-4). Some of these groups have been followed for many years. Important data are available in spite of the complexities of long-term epidemiological studies, such as mobility of populations, non-uniformity of occupational histories, and inadequacy of dosimetry. These studies will be discussed at length by my colleagues in this symposium.

High Natural Background Areas

There are populations exposed to lifetime doses of very high natural background radiation; two are those living in the monazite sands regions of Brazil and India, where they have resided for many generations. Attempts to obtain reliable epidemiological data from these populations have failed due primarily to the complications of collecting human epidemiological data and further confounded by local cultural, religious, and political practices.

Natural background radiation may vary from one geographic region to the next (1). Attempts to correlate background dose with human epidemiological data are confounded by errors and lack of uniformity in the dosimetric estimates of radiation levels, and by varying quality of vital statistics information among the various communities, states, regions, and countries (1-4). The sources of bias introduced by these factors have thus far been greater than differences that are likely to be of any value.

What Are the Sources of Epidemiological Data for the Estimation of Excess Cancer Risk in Exposed Human Populations?

The tissues and organs about which we have the most reliable epidemiological data on radiation-induced cancer in man, obtained from a

variety of sources from which corroborative risk coefficients have been estimated, include the bone marrow, the thyroid, the breast, and the lung (1,2). The data on bone and the digestive organs are, at best, preliminary, and do not approach the precision of the others. For several of these tissues and organs, risk estimates are obtained from very different epidemiological surveys, some followed for over 30 years, and with adequate control groups. There is good agreement when one considers the lack of precision inherent in the statistical analyses of the case-finding and cohort study populations, variability in ascertainment and clinical periods of observation, age, sex and racial structure, and different radiation dose levels, and constraints on data from control groups.

The most reliable data have been those of the risk of leukemia, which come from the Japanese atomic bomb survivors (17,18,38), the ankylosing spondylitis patients treated with x-ray therapy in England and Wales (26), the metropathia patients treated with radiotherapy for benign uterine bleeding (30), the tinea capitis patients treated with radiation for ringworm of the scalp (31), and the early radiologists (32,33). There is evidence of an age-dependence and a dose-dependence, a relatively short latent period of a matter of a few years, and a relatively short period of expression, some 10 years. This cancer is uniformly fatal.

The data on thyroid cancer are more complex. These surveys include the large series of children treated with radiation to the neck and mediastinum for enlarged thymus (34), children treated to the scalp for tinea capitis (31), and the Japanese atomic bomb survivors (17) and Marshall Islanders (20) exposed to nuclear explosions. Here, there is an age-dependence and sex-dependence--children and females appear more sensitive. Although the induction rate is high, the latent period is relatively short, and it is probable that no

increased risk will be found in future follow-up of these study populations. In addition, most tumors are either thyroid nodules or benign or treatable tumors, and only a few are fatal.

Much information has become available on radiation-induced breast cancer in women (35,39). The surveys include primarily women with tuberculosis who received frequent fluoroscopic examinations for artificial pneumothorax (25), postpartum mastitis patients treated with radiotherapy (36), and the Japanese atomic bomb survivors in Hiroshima and Nagasaki (17). Here, there is an age-dependence and dose-dependence, as well as a sex-dependence. The latent period is long, some 20 to 30 years. Perhaps about half of these neoplasms are fatal.

Another relatively sensitive tissue, and a complex one as regards radiation dose involving parameters of the special physical and biological characteristics of the radiation quality, is the epithelial tissue of the bronchus and lung. These surveys include the Japanese atomic-bomb survivors (17), the uranium miners in the United States and Canada (37), and the ankylosing spondylitis patients in England and Wales (26). There is some evidence of age-dependence from the Japanese experience, and a relatively long latent period. This cancer is uniformly fatal.

The risk of radiation-induced bone sarcoma, based primarily on surveys of the radium and thorium patients who had received the radioactive substances for medical treatment, or persons who ingested these materials in the course of their occupations (28), is low. For all other tumors arising in various organs and tissues of the body, values are extremely crude and estimates are, at best, preliminary.

What Can We Conclude?

Of various somatic effects that might be produced by ionizing radiation at low levels of dose and dose rate, cancer-induction is presently considered to

be the most important potential hazard to health in exposed human populations. Studies of irradiated human populations indicate a dose-dependent increase in the incidence of most types of cancer. The dose-response relationships for these cancers are consistent with a range of linear, linear-quadratic, and quadratic relationships between cancer incidence and dose. The data on the influence of dose rate in man are limited and at present fail to indicate a reduction of risk per rad with decreasing dose rate. The available dose-incidence data suggest an age-dependency and a sex-dependency; the overall susceptibility appears higher in children than in adults.

All tissues of the body are susceptible to cancer-induction by radiation. The epidemiological data are inadequate to define the dose-response relationships at doses below 25 to 50 rems. Data for high-LET radiation are only fragmentary; these suggest a high RBE with little change in effectiveness per rad with decreasing dose rate. Data for low-LET radiation, on the other hand, generally show a decrease in the effectiveness per rad with decreasing dose and dose rate.

Numerical estimation of the risk of radiation-induced cancer in man must necessarily be based primarily on human dose-incidence data. However, risk estimation at very low doses and low dose rates at present must also necessarily depend on extrapolation from observation at higher doses and higher dose rates, based on assumptions about the dose-incidence relationships and the mechanisms of carcinogenesis. Improvements in our knowledge of the carcinogenic effectiveness of ionizing radiation will depend on elucidation of mechanisms of carcinogenesis, especially at the very earliest stages of malignant transformation, and on the provision of empirical dose-incidence data for low doses both in human populations and in laboratory animals experiments, insofar as this is possible.

And finally, we must conclude that the estimation of the carcinogenic risk of low-dose, low-LET radiation is subject to numerous uncertainties. The greatest of these concerns is the shape of the dose-response curve. Others include the length of the latent period, the RBE for fast neutrons and alpha radiation relative to gamma and x-radiation, and the period during which the radiation risk is expressed, the model used in projecting risk beyond the period of observation, the effect of dose rate or dose fractionation, and the influence of differences in the natural incidence of specific types of cancer. In addition, uncertainties are introduced by the biological risk characteristics of humans, for example, the effect of age at irradiation, the influence of any disease for which the radiation was given therapeutically, and the influence of length of observation or follow-up of the study populations. The collective influence of these uncertainties is such as to deny great credibility to any estimates of human cancer risk that can be made for low-dose, low-LET radiation. Nevertheless, despite all the uncertainties I have chosen to discuss, there is greater knowledge of the risks of radiation than of any other potentially hazardous physical or chemical agent in the environment.

AKNOWLEDGEMENTS

The author gratefully acknowledges the generous assistance of his many colleagues in epidemiology, statistics, and the radiation sciences, and from whose labors and work he has drawn on for this presentation. He thanks Mrs. Diana Morris and Mrs. Kathleen Becky for generous help in the preparation of this manuscript, and Mr. Robert Stevens for help with the illustrations.

This work was supported by the Office of Health and Environmental Research of the U.S. Department of Energy under Contract DE-AC03-76SF00098, and the Environmental Protection Agency.

REFERENCES

1. Committee on the Biological Effects of Ionizing Radiations. National Academy of Sciences-National Research Council. *The Effects on Populations of Exposure to Low Levels of Ionizing Radiation*; 1980. Washington, D.C., 1980.
2. United Nations Scientific Committee on the Effects of Atomic Radiation. *Sources and Effects of Ionizing Radiation*. United Nations, New York, 1977.
3. Advisory Committee on the Biological Effects of Ionizing Radiations. National Academy of Sciences-National Research Council. *The Effects on Populations of Exposure to Low Levels of Ionizing Radiation*. Washington DC, 1972.
4. Ionizing Radiations: Levels and Effects. A report of the United Nations Scientific Committee on the Effects on Atomic Radiation to the General Assembly, with Annexes. United Nations, New York, 1972.
5. Upton AC: Comparative observations on radiation carcinogenesis and animals, pp 631-675 in *Carcinogenesis, A Broad Critique*, Williams and Wilkins Co., Baltimore, MD, 1967.
6. Upton AC: Effects of radiation on man. *Ann Rev Nucl Sci*, 1968.
7. Upton AC: Radiobiological effects of low doses: Implications for radio-biological protection. *Radiation Res* 71:51-74, 1977.
8. Casarett GW: In: *Pathogenesis of Radionuclide-Induced Tumors in Radionuclide Carcinogenesis*. Edited by CL Sanders, RN Busch, JE Ballon, and DD Möhlm. US Atomic Energy Commission Tech Information Service, Oak Ridge, Tenn, pp 1-14, 1973.
9. National Council on Radiation Protection and Measurements. NCRP Report No. 64. *Influence of Dose and its Distribution in Time on Dose-Response Relationships for Low-LET Radiations*. Washington DC, 1980.

10. Rossi HH and Kellerer AA: Radiation carcinogenesis at low dose. *Science* 175: 200, 1972.
11. National Council on Radiation Protection and Measurements. NCRP Report No. 43. *Review of the Current State of Radiation Protection Philosophy*. Washington DC, 1975.
12. International Commission on Radiological Protection. *Protection Against Ionizing Radiation from External Sources*, ICRP Publication 15. Pergamon Press, Oxford, 1970. *Data for Protection Against Ionizing Radiation from External Sources: Supplement to ICRP Publication 15*, ICRP Publication 21, Pergamon Press, Oxford, 1973.
13. Brown JM: The shape of the dose-response curve for radiation carcinogenesis. Extrapolation to low doses. *Radiation Res.* 71:31-50, 1977.
14. Fabrikant JI: The BEIR III controversy. *Radiation Res.* 84: 361-368, 1980.
15. Fabrikant JI: The BEIR III Report: Origin of the controversy. *AJR* 136:209-214, 1981.
16. Boice JD Jr, Land CE, Shore RE, Norman JE and Tokunaga M: Risk of breast cancer following low-dose exposure. *Radiology* 131: 589-597, 1979.
17. Beebe GW, Kato H and Land CE: Mortality Experience of Atomic Bomb Survivors 1950-1974. Life Span Study Report 8. Radiation Effects Research Foundation Technical Report RERF TR 1-77, National Academy of Sciences, Washington DC, 1977.
18. Ishimaru, T, Utake M and Ischimaru M: Dose-response relationship of neutrons and γ -rays to leukemia incidence among atomic-bomb survivors in Hiroshima and Nagasaki by type of leukemia, 1950-1971. *Radiation Res* 77:377-394, 1979.

19. Ichimaru M, Ishimaru T, Belsky J, Tomiyasu T, Sadamori N, Hoshino T, Tomonaga M, Shimizu N and Okada H: Incidence of Leukemia in Atomic Bomb Survivors, Hiroshima and Nagasaki, 1950-71, by Radiation Dose, Years after Exposure, Age, and Type of Leukemia. Radiation Effects Research Foundation Technical Report RERF TR 10-76, Radiation Effects Research Foundation, Hiroshima, 1976.
20. Conard RA: Summary of thyroid findings in Marshalllese 22 years after exposure to radioactive fallout in radiation-associated thyroid carcinoma in Radiation-Associated Thyroid Carcinoma. Edited by DeGroot LJ, pp. 241-257. Academic Press, New York, 1977.
21. Stewart A, Webb J and Hewitt D: A survey of childhood malignancy. Brit Med J 1:1495, 1958.
22. MacMahon B: Prenatal x-ray exposure and childhood cancer. J Natl Cancer Inst 28:1773, 1962.
23. Gibson R, Graham S, Lichtenfeld A, Schuman I, Dowd JE, and Levin ML: Irradiation in the epidemiology of leukemia among adults, J Nat Cancer Inst 48: 301, 1972.
24. MacKenzie I: Breast cancer following multiple fluoroscopies. Cancer 19: 1, 1965.
25. Hydren JA and Quinlan JJ: Breast carcinoma following multiple fluoroscopies with pneumothorax treatment of pulmonary tuberculosis. Ann Roy Coll Physicians Can 7:45-51, 1974.
26. Court-Brown WM and Doll R: Mortality from cancer and other causes from radiotherapy for ankylosing spondylitis. Brit Med J 2:1327-1332, 1965.
27. Spiess H and Mays CH: Bone cancers induced by ^{224}Ra (THY) in children and adults. Health Phys 19:713, 1970.

28. Mays CW and Spiess H: Bone sarcoma risks to man from ^{224}Ra , ^{226}Ra and ^{239}Pu in Biological Effects of ^{224}Ra . benefit and risk of Therapeutic Application. Edited by Miller WA and Ebert HG, pp. 168-181, Nyhoff Medical Divison, The Hague, 1978.
29. ICRP Publ 14, Radiosensitivity and Special Distribution of Dose, prepared two Task Groups of Committee 1 of the International Commission of Radiological Protection, Pergamon Press, New York, 1969.
30. Smith PG and Doll R: Late effects of x-irradiation in patients for metropathia haemorrhagica. *Brit J Radiol* 49:223-232, 1976.
31. Shore RE, Albert RE and Pasternack BS: Follow-up of patients treated by x-ray epilation for tinea capitis. *Arch Environ Health* 31:21-29, 1976.
32. Matanoski GN, Seltzer R, Sartwell PE et al: The current mortality rates of radiologists and other physician specialists: specific causes of death. *Amer J Epid* 101:119-210, 1975.
33. Matanoski GM: Risk of cancer associated with occupational exposure in radiologists and other radiation workers, in 1980 International Symposium on Cancer. Grune and Stratton, New York, to be published, 1981.
34. Hempelmann LH, Hall WJ, Phillips M, Cooper RA and Ames KR: Neoplasms in persons treated with x-rays in infancy: Fourth survey in 20 years. *J Natl Cancer Inst* 55:510-530, 1975.
35. Upton AC, Beebe GW, Brown JM, Quimby EH, and Shellabarger C: Report of NCI ad hoc working group on the risks associated with mammography in mass screening for the detection of breast cancer. *J Natl Cancer Inst* 59:480-493, 1977.
36. Hempelmann LH, Kowaluk E, Mansur PS, Pasternack BS, Albert RE, and Haugne GE: Breast neoplasms in women treated with x-rays for acute post-partum mastitis. *J Natl Cancer Inst* 59:813-822, 1977.

37. Health Effects of Alpha-Emitting Particles in the Respiratory Tract.

Report of ad hoc Committee on "Hot Particles" of the Advisory Committee on the Biological Effects of Ionizing Radiations. National Academy of Sciences, Washington DC, 1974.

38. Jablon S and Kato H: Studies of the mortality of A-bomb survivors.

Radiation dose and mortality, 1950-1960. Rad Res 50: 649, 1972.

39. Mole RH: The sensitivity of the human breast to cancer induction by

ionizing radiation. Brit J Radiol 51:401-405, 1978.

FIGURE LEGENDS


Figure 1. General dose-response model for radiation carcinogenesis based on radiobiological experiments and epidemiological studies. I , cancer incidence; D , radiation dose; α_0 , spontaneous incidence of cancer in the population; α_1 , α_2 , β_1 , β_2 are positive coefficients.

Figure 2. Shapes of various dose-response relationships of radiation-induced cancer in mammalian radiobiology and in epidemiological surveys. These are derived from the general dose-response model, and include the linear, the linear-quadratic, and the pure quadratic dose-response curves.

Figure 3. Left: Relative risk of radiation-induced leukemia in Japanese atomic bomb survivors in Hiroshima plotted against T65 dose (perma) (17). Comparison of the Life Span Study (LSS) death certificate data (solid line) and the total Leukemia Registry (dash line) data. The Hiroshima atomic bomb contained a relatively large fraction (approximately 19 percent) of neutrons.

Right: Relationship of radiation-induced leukemia in Japanese atomic-bomb survivors in Nagasaki plotted against T65 dose (kernia) (17). Comparison of the LSS death certificate data (solid line) and the total Leukemia Registry data (dash line). The Nagasaki atomic bomb contained a relatively small fraction (approximately 1 percent) of neutrons.

Figure 4. Incidence of excess breast cancer in irradiated women plotted against radiation dose. Upper Left: Japanese atomic bomb survivors. Upper Right: women fluoroscoped in Massachusetts tuberculosis sanatorium. Lower Left: post-partum mastitis patients. Lower Right: women fluoroscoped in Nova Scotia tuberculosis sanatorium. The excess incidence is expressed in terms of women-years (WY) at risk.



SHAPES OF DOSE RESPONSE CURVES




figure 2




Figure 3

XBL815-3791




Figure 4

YB1815 1792

This report was done with support from the Department of Energy. Any conclusions or opinions expressed in this report represent solely those of the author and not necessarily those of The Regents of the University of California, the Lawrence Berkeley Laboratory or the Department of Energy.

Reference to a company or product name does not imply approval or recommendation of the product by the University of California or the U.S. Department of Energy to the exclusion of others that may be suitable.

TECHNICAL INFORMATION DEPARTMENT
UNIVERSITY OF BERKELEY, AGRICULTURAL
UNIVERSITY OF CALIFORNIA
BERKELEY, CALIFORNIA 94726